Hallucinogen Rating Scale

The Hallucinogen Rating Scale (HRS) is a psychometric scale for measuring the subjective effects of hallucinogens like psychedelic drugs and other psychoactive drugs. It includes 100 items that are mostly on a 5-point Likert scale and 6 factors/subscales (somaesthesia, affect, perception, cognition, volition, and intensity). The HRS is one of the most widely used scales for measuring hallucinogen effects, following the 5D-ASC and 11-ASC scales. It has been revised several times and has been translated into and validated in several different languages. The HRS was developed by Rick Strassman and colleagues and first described in 1992. It was first developed and used to assess the hallucinogenic effects of the psychedelic drug dimethyltryptamine (DMT). Subsequently, it has also been used with a variety of other psychoactive drugs, including psilocybin, ayahuasca, 2C-B, meta-chlorophenylpiperazine (mCPP), ketamine, dextromethorphan (DXM), salvinorin A/Salvia divinorum, Δ9-tetrahydrocannabinol (THC), d-amphetamine, d-methamphetamine, 4-fluoroamphetamine, methylphenidate, MDMA, and MDEA.

See also

References

  1. 1 2 3 4 5 Herrmann Z, Earleywine M, De Leo J, Slabaugh S, Kenny T, Rush AJ (2023). "Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials". J Psychoactive Drugs. 55 (4): 501–517. doi:10.1080/02791072.2022.2125467. PMID 36127639.
  2. 1 2 3 Prugger J, Derdiyok E, Dinkelacker J, Costines C, Schmidt TT (November 2022). "The Altered States Database: Psychometric data from a systematic literature review". Sci Data. 9 (1): 720. doi:10.1038/s41597-022-01822-4. PMC 9684144. PMID 36418335.
  3. 1 2 3 4 5 6 Hovmand OR, Poulsen ED, Arnfred S (January 2024). "Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics". J Psychopharmacol. 38 (1): 19–32. doi:10.1177/02698811231200019. PMC 10851631. PMID 37969069.
  4. 1 2 3 4 de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, Tófoli LF, Daldegan-Bueno D (2023). "Systematic Review of Psychometric Instruments Used in Research with Psychedelics". J Psychoactive Drugs. 55 (3): 359–368. doi:10.1080/02791072.2022.2079108. PMID 35616606.
  5. 1 2 Bouso JC, Pedrero-Pérez EJ, Gandy S, Alcázar-Córcoles MÁ (September 2016). "Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens". Hum Psychopharmacol. 31 (5): 356–372. doi:10.1002/hup.2545. PMID 27470427.
  6. ↑ Riba J, Rodríguez-Fornells A, Strassman RJ, Barbanoj MJ (May 2001). "Psychometric assessment of the Hallucinogen Rating Scale". Drug Alcohol Depend. 62 (3): 215–223. doi:10.1016/s0376-8716(00)00175-7. PMID 11295326.
  7. 1 2 Calder AE, Qualls C, Hasler G, Elmiger D, Strassman R (March 2025). "The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample". Biol Psychiatry Glob Open Sci. 5 (2) 100436. doi:10.1016/j.bpsgos.2024.100436. PMC 11804565. PMID 39926700.
  8. ↑ Strassman, R. (1992). Subjective effects of DMT and the development of the Hallucinogen Rating Scale. Newsletter of the Multidisciplinary Association for Psychedelic Studies, 3(2), 2–. https://scholar.google.com/scholar?cluster=14254000933395729662
  9. ↑ Strassman RJ (1994). "Human hallucinogenic drug research: regulatory, clinical, and scientific issues" (PDF). NIDA Res Monogr. 146: 92–123. PMID 8742796.
  10. ↑ Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (February 1994). "Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale". Arch Gen Psychiatry. 51 (2): 98–108. doi:10.1001/archpsyc.1994.03950020022002. PMID 8297217.